Belite Bio Inc. research snapshot
BLTE AI stock analysis currently reads Belite Bio Inc. as a clinical-stage biopharmaceutical company whose value depends mainly on tinlarebant (LBS-008), an oral RBP4 antagonist being developed for Stargardt disease type 1 and geographic atrophy (dry AMD). The Phase 3 DRAGON trial met its primary endpoint with a 35.7% reduction in retinal lesion growth, and Belite Bio completed a rolling New Drug Application to the FDA for tinlarebant on June 12, 2026. At the August 4, 2026 data cutoff, BLTE closed at $154.79 on August 3, implying a market capitalization of about $6.1 to $6.2 billion. This BLTE AI stock analysis uses conditional scenarios and source-backed facts for information only. It is not investment advice.
Current price
$154.79 at the August 3, 2026 Nasdaq close
Market cap
$6.20 billion (MarketBeat) from 40.09 million shares; StockAnalysis reports $6.09 billion from 39.34 million shares, a 1.8% variance
AI score
58 / 100
Rating
Clinical-stage retinal biotech with positive Phase 3 data and a completed FDA NDA, but no approved product or revenue
Trend status
Strong 52-week uptrend from $60 to $200; the August 3 close of $154.79 sits above the 50-day and 200-day moving averages after an early-2026 correction
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Belite Bio is a focused clinical-stage biotech built around tinlarebant, an oral RBP4 antagonist for retinal disease. The Phase 3 DRAGON trial met its primary endpoint, but the company still has no approved product or revenue. | High |
| Moat | The potential moat rests on the RBP4 mechanism, orphan drug exclusivity (US, Europe, Japan, Switzerland), rare pediatric and breakthrough designations, and issued patents. No brand, network effects, or commercial scale exist yet. | Low-medium |
| Management | CEO Tom Lin also chairs parent Lin Bioscience International. The team completed the NDA on schedule and communicates trial data consistently. Insider ownership estimates vary from 1.82% (StockAnalysis) to 13.29% (MarketBeat), and insiders sold about $3.1 million in the last three months. Commercial execution is unproven. | Low-medium |
| Financial trend | No product revenue and a TTM net loss of about $90 million, after a $77.6 million loss in fiscal 2025. Cash and investments of about $492 million as of March 2026 with no material debt give a multi-year runway. | Medium |
| Valuation | At roughly $6.1 to $6.2 billion of equity value with no revenue, BLTE has no meaningful PE or P/S ratio. The price reflects probability-weighted value for tinlarebant approval and commercial success, with book value near $23 per share. | Medium |
| Technical trend | The August 3 close of $154.79 is above the 50-day moving average of $148.10 and the 200-day moving average of $150.44, and the stock is up 135.5% over 52 weeks. It remains below the 52-week high of $200. | Medium |
| Risk level | Risk is high. A single FDA decision determines most of the equity value, the company has no revenue, trading liquidity is thin, short interest is moderate, and insiders have been net sellers. The strong cash balance reduces financing risk but not clinical risk. | High |
| AI confidence | Confidence is higher for observable facts such as trial results, NDA status, price, market cap, cash, and analyst targets. It is lower for forecasts that assume approval timing, label breadth, pricing, or market share. | Medium data confidence |
| Investment certainty | The tinlarebant clinical thesis is credible and better capitalized than before, but unproven. Certainty depends on FDA acceptance, the PDUFA outcome, DRAGON II and PHOENIX data, and first commercial execution. | Low |
BLTE AI stock forecast
The BLTE AI stock forecast is a conditional framework, not a price promise. Standard EPS-based valuation is not decision-useful because the company has negative earnings. The ranges below are market-repricing bands tied to FDA review, approval, label, and commercial execution, updated to the August 4, 2026 data cutoff.
$220 to $320
More likely if the FDA accepts the NDA and assigns an early PDUFA date, tinlarebant is approved with a broad label, orphan exclusivity supports pricing, DRAGON II and the PHOENIX geographic atrophy trial progress well, and the first launch execution is clean.
$110 to $210
More likely if the NDA review advances but approval timing, label breadth, pricing, or market share stay uncertain. The stock continues to trade on regulatory milestones, clinical data, and earnings reports rather than current revenue.
$45 to $95
More likely if the FDA issues a complete response letter, requests additional work, safety or manufacturing concerns emerge, DRAGON II or PHOENIX data disappoint, or the approved label and pricing come in narrow. The strong cash position lowers dilution risk but does not prevent a sharp reset on a failed approval.
BLTE AI technical analysis
BLTE AI technical analysis shows a stock that rallied from a 52-week low of $60.00 to a high of $200.00, corrected in early 2026, and now trades at $154.79, above both its 50-day and 200-day moving averages. The 50-day and 200-day averages are sourced from S&P data via StockAnalysis. High event risk around the FDA review makes conventional technical signals less reliable.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $154.79 | August 3, 2026 Nasdaq close. The session range was $152.88 to $157.56 with after-hours trading at $156.93. MarketBeat and StockAnalysis quote data. |
| Near support | $148 to $151 | The 50-day moving average of $148.10 and the 200-day moving average of $150.44 form a cluster. A close below this zone would weaken the near-term structure. |
| Key support | $134 to $138 | The lower end of the 50-day range at $134.93. Losing this zone would signal a deeper pullback from the early-2026 correction. |
| Major support | $100 | Psychological round number well below the current price. A break below would put the long-term post-NDA thesis in question. |
| Near resistance | $157 to $161 | The upper end of the 50-day range at $161.08 and recent session highs. A close above with volume would improve short-term momentum. |
| Major resistance | $200 | The 52-week high and a round number. A decisive break above would put the stock into price discovery territory. |
| Moving averages | 50-day $148.10; 200-day $150.44 | S&P data via StockAnalysis, August 3, 2026. The stock trades above both averages. |
| Momentum | RSI 51.88; +135.5% over 52 weeks; +158% from the 52-week low; YTD -3.2% | Momentum is neutral-to-positive on the relative strength index, strongly positive over 52 weeks, and slightly negative year to date. Yahoo reports a slightly different YTD figure of +0.56% as of July 31, 2026, reflecting source timing. |
| Volume | 191,493 shares on August 3; average 194,749 | Volume is close to average and modest in absolute terms. Thin liquidity can amplify price moves on FDA or clinical news. |
| Volatility | 52-week range $60.00 to $200.00 | The wide range reflects the binary nature of a pre-approval biotech. Gap risk dominates daily volatility measurement. |
| Invalidation | Close below $134.93, then deeper risk toward $100 | A close below the 50-day range floor would signal a correction. A break below $100 would challenge the entire bullish thesis. |
BLTE AI trading strategy
The BLTE AI trading strategy is a non-personal framework for a milestone-driven biotechnology stock. Any use should include live quotes, position sizing, the FDA calendar, SEC filing monitoring, and explicit rules for binary event gaps. It is not investment advice.
Look for a close above the $157 to $161 resistance zone, then monitor for a retest that holds with volume and no adverse FDA or clinical news. A later break above $200 would confirm a new high but would not remove regulatory risk.
Treat a close below the $148 to $151 moving-average cluster as a failed near-term breakout. A close below $134.93 signals a deeper correction.
A pullback toward the $134 to $138 zone can be monitored only after price stabilizes and the tinlarebant thesis remains intact. Compare any bounce with volume, the FDA review timeline, and new filings.
Do not treat a sharp decline as automatically oversold. A complete response letter or negative clinical data can gap the stock through support without a technical bounce, even with a strong cash balance.
Track the FDA NDA acceptance and PDUFA date, DRAGON II enrollment, PHOENIX geographic atrophy progress, the Q2 2026 earnings report estimated for early to mid August 2026, cash and spend, and insider activity.
Reduce confidence if the FDA issues a complete response letter, Phase 2/3 data disappoint, spending accelerates sharply, or insiders sell material positions ahead of key catalysts.
Investment research summary
Belite Bio is trying to turn one oral RBP4 antagonist into the first approved therapy for Stargardt disease type 1 and a candidate for geographic atrophy. Tinlarebant reduces the accumulation of vitamin A-based toxins in the eye. The company has positive Phase 3 data and a completed NDA, not a recurring product business yet.
The current moat is prospective: the RBP4 mechanism, orphan drug and breakthrough designations, issued patents, and accumulated clinical data. There are no meaningful network effects, switching costs, or commercial brand today. Gene therapies, complement inhibitors, and other retinal approaches can limit adoption even after approval.
The thesis can fail if the FDA issues a complete response letter, safety or manufacturing concerns emerge, the Stargardt label is narrow, geographic atrophy data disappoint, or the launch is slow. Low trading liquidity and net insider selling amplify downside in a negative catalyst event. The roughly $492 million cash balance reduces but does not remove dilution risk.
CEO Tom Lin also chairs parent Lin Bioscience International, creating strategic alignment and related-party governance considerations. The team delivered the NDA on schedule and reported the positive DRAGON data. Insider ownership estimates differ widely by source, insiders sold about $3.1 million in the last three months, and the record of post-approval commercialization is unproven.
Retinal disease therapeutics have strong demographic tailwinds from aging populations. Stargardt disease type 1 affects about 53,000 people in the US with no approved therapy, and geographic atrophy is an emerging market with recently approved complement inhibitors. An oral therapy could offer convenience over injected alternatives, but competition is evolving quickly.
At an equity value of about $6.1 to $6.2 billion, BLTE has no useful PE, P/S, or FCF yield because revenue and earnings are negative. The market capitalization implies a substantial probability-weighted value for tinlarebant approval and commercial success. The strong cash position improves the balance sheet risk, but the margin of safety is still thin for a binary-outcome pre-revenue biotech trading below but near its high zone.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| BLTE latest completed-session price | $154.79 at the August 3, 2026 Nasdaq close; after-hours $156.93 | MarketBeat quote data | August 4, 2026 |
| Market capitalization | $6.20 billion (MarketBeat, 40.09 million shares) versus $6.09 billion (StockAnalysis, 39.34 million shares); 1.8% variance | MarketBeat and StockAnalysis | August 4, 2026 |
| Shares outstanding | 40,085,000 (MarketBeat) versus 39.34 million (StockAnalysis); up 13.95% year over year | MarketBeat and StockAnalysis | August 4, 2026 |
| EPS and net income | TTM EPS of -$2.53 to -$2.66 by source; TTM net loss of about $90.27 million; fiscal 2025 net loss of $77.61 million | StockAnalysis (Fiscal.ai) and MarketBeat | August 4, 2026 |
| Cash position and debt | Cash and investments of $492.42 million at December 31, 2025 and about $492 million as of March 2026; no material debt; multi-year cash runway | StockAnalysis (Fiscal.ai) and Simply Wall St | August 4, 2026 |
| Book value and P/B | Book value per share of $22.97 at fiscal 2025 (StockAnalysis) and $20.54 (MarketBeat); P/B ratio 7.54 to 7.69 by source | MarketBeat and StockAnalysis | August 4, 2026 |
| Q1 2026 earnings | EPS of -$0.34 versus the -$0.60 consensus, a beat of $0.26; reported May 15, 2026; Q2 2026 estimated August 7 to 10, 2026 | MarketBeat earnings data | August 4, 2026 |
| NDA submission status | Rolling New Drug Application to the FDA for tinlarebant in Stargardt disease type 1 completed June 12, 2026; initiated April 2026 under Breakthrough Therapy Designation; 60-day FDA review pending | Belite Bio press release via GlobeNewswire | August 4, 2026 |
| Phase 3 DRAGON trial | 104 subjects across 11 jurisdictions with 2:1 randomization; primary endpoint met with a 35.7% reduction in retinal lesion growth; ASRS 2026 oral presentation with additional positive secondary endpoint data (qAF stable to slightly decreased versus about 20% increase in placebo at month 25) | Belite Bio press release via GlobeNewswire | August 4, 2026 |
| Regulatory designations | Breakthrough Therapy, Fast Track, and Rare Pediatric Disease in the US; Orphan Drug in the US, Europe, Japan, and Switzerland; Sakigake designation in Japan | Belite Bio press releases | August 4, 2026 |
| Analyst consensus and price targets | Moderate Buy consensus (MarketBeat score 2.88, 8 analysts) with an average price target of $203 (high $266, low $132); StockAnalysis reports a Strong Buy consensus with a $210.50 average target | MarketBeat and StockAnalysis | August 4, 2026 |
| Technical snapshot | 50-day moving average $148.10; 200-day moving average $150.44; RSI 51.88; 52-week change +135.5%; beta -1.22 | StockAnalysis (S&P Global) | August 4, 2026 |
| Short interest | 1.315 million shares short, 3.78% of float, 7.1 days to cover as of July 15, 2026 (MarketBeat); 6.32% of shares outstanding (StockAnalysis) | MarketBeat and StockAnalysis | August 4, 2026 |
| Ownership structure | Insider ownership 13.29% (MarketBeat) versus 1.82% (StockAnalysis); institutional ownership 0.53% (MarketBeat) versus 15.88% (StockAnalysis); insiders sold about $3.1 million in the last three months | MarketBeat and StockAnalysis | August 4, 2026 |
| 52-week price range | $60.00 to $200.00 | MarketBeat, StockAnalysis, and Yahoo Finance | August 4, 2026 |
This BLTE AI stock analysis page is an informational research tool only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are conditional scenarios based on available data as of August 4, 2026 and can be wrong if regulatory decisions, clinical results, competition, financing needs, commercialization execution, or market sentiment change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
